The German authorities have given approval to Hoechst AG for the construction and operation of a $66.8 million plant to produce human insulin from genetically-engineered bacteria. Hoechst's application has been in the pipeline for over two years.
Part of the overall project, designated Fermtec, has been approved under genetic engineering legislation, and the Chemtec and Insultec parts of the plant projects have been allowed under environmental emissions legislation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze